The following is the information presented:

  ♦    OralPAS Technology platform

  ♦    An open-label, exploratory, limited dose escalation study to evaluate the pharmacokinetics (PK), safety and tolerability of gemcitabine hydrochloride oral formulation in subjects with malignant tumors

About Gemcitabine hydrochloride oral formulation (GemOral^®)

GemOral^® was developed based on InnoPharmax's proprietary formulations. Lower dose is designed with novel oral formulation due to metronomic chemotherapy consideration (frequently administration with low dose). By metronomic chemotherapy, GemOral^® can reduces the level of toxicity significantly. GemOral^® can submit through 505(b)(2) pathway, which offers a unique opportunity for rapid approval.

Up to date, the clinical data of GemOral^® has been shown its better pharmacokinetic characteristics. Due to its new administration route and unique formulation, GemOral^® has been shown its clinical benefits in several new indications with promising in-vivo data.

About InnoPharmax

InnoPharmax is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology and oncology. It develops and acquires potential drug candidates for further development as well as commercialization, and uses internally developed drug delivery technology platforms for improving the safety and effectiveness of currently available drugs to provide better medical choices in these specific disease categories.